US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Takeda Pharmaceutical Co Ltd

14.19

-0.1700-1.18%

Pre-market: 14.05-0.1400-0.99%04:31 EDT

Volume:5.38M

Turnover:75.87M

Market Cap:44.79B

PE:63.21

High:14.31

Open:13.56

Low:13.55

Close:14.36

Loading ...

Overview Company News Filings

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading

MT Newswires Live

Takeda Canada says Health Canada expands marketing authorization for HyQvia

Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus

MT Newswires Live

ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

TAK or DSNKY: Which Is the Better Value Stock Right Now?

Will ADMA Biologics Stock Continue Its Momentum in 2025?

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

MT Newswires Live

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis

Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?

Takeda announces EMA approval for Takhzyro two mL pre-filled pen option

Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug

MT Newswires Live

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TAK/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TAK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TAK\",,,,,undefined,":{"symbol":"TAK","market":"US","secType":"STK","nameCN":"Takeda Pharmaceutical Co Ltd","latestPrice":14.19,"timestamp":1747080000000,"preClose":14.36,"halted":0,"volume":5381680,"hourTrading":{"tag":"盘前","latestPrice":14.05,"preClose":14.19,"latestTime":"04:31 EDT","volume":5,"amount":70.25,"timestamp":1747125109422},"delay":0,"floatShares":3144798052,"shares":3156322898,"eps":0.224477,"marketStatus":"Pre-Mkt","change":-0.17,"latestTime":"05-13 05:30:18 EDT","open":13.56,"high":14.31,"low":13.55,"amount":75873257.59828,"amplitude":0.052925,"askPrice":14.03,"askSize":80,"bidPrice":13.81,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.224477,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747143000000},"marketStatusCode":1,"adr":0,"adrRate":0.5,"listingDate":1545627600000,"exchange":"NYSE","adjPreClose":14.19,"dividendRate":0.046686,"preHourTrading":{"tag":"盘前","latestPrice":14.05,"preClose":14.19,"latestTime":"04:31 EDT","volume":5,"amount":70.25,"timestamp":1747125109422},"postHourTrading":{"tag":"盘后","latestPrice":14.19,"preClose":14.19,"latestTime":"19:48 EDT","volume":4376,"amount":62098.4692,"timestamp":1747093736665},"volumeRatio":2.0116444582815878,"impliedVol":0.3778,"impliedVolPercentile":0.6988},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TAK\",,,,,undefined,":{"symbol":"TAK","floatShares":3144798052,"roa":"1.91%","roe":"1.52%","lyrEps":0.228224,"volumeRatio":2.0116444582815878,"shares":3156322898,"dividePrice":0.662382,"high":14.31,"amplitude":0.052925,"preClose":14.36,"low":13.55,"week52Low":12.575,"pbRate":"0.96","psRate":"1.45","week52High":15.425,"institutionHeld":0.1164,"latestPrice":14.19,"committee":0.851852,"eps":0.224477,"divideRate":0.046686,"volume":5381680,"delay":0,"ttmEps":0.224477,"open":13.56,"prevYearClose":13.24,"prevWeekClose":14.36,"prevMonthClose":15.29,"prevQuarterClose":14.87,"fiveDayClose":15.38,"twentyDayClose":13.88,"sixtyDayClose":13.62},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TAK\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525834416","title":"AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2525834416","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525834416?lang=en_us&edition=fundamental","pubTime":"2025-04-08 14:00","pubTimestamp":1744092000,"startTime":"0","endTime":"0","summary":"RINVOQ is the first and only oral Janus kinase  inhibitor approved in the European Union  to treat adult patients with giant cell arteritis . The approval is supported by data from the pivotal Phase 3 SELECT-GCA trial which demonstrated that RINVOQ achieved the primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure and complete remission 1. This marks the eighth approved indication for RINVOQ in the EU2. NORTH CHICAGO, Ill., April 8, 2025 /PRNewswire/ -- AbbVie  today announced that the European Commission  granted marketing authorization to RINVOQ  for the treatment of giant cell arteritis  in adult patients. RINVOQ is the first and only oral JAK inhibitor approved in the EU, as well as Iceland, Liechtenstein and Norway, for the treatment of adult patients with GCA.GCAis an autoimmune disease that causes inflammation of the temporal and other cranial arteries, the aorta, and other large and medium ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-announces-european-commission-approval-060000872.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-announces-european-commission-approval-060000872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1718418525.SGD","LU1551013342.USD","IE00BJT1NW94.SGD","LU1934455194.USD","IE00BFTCPJ56.SGD","BK4156","LU0211328371.USD","SG9999015945.SGD","IE00BVYPNV92.GBP","LU1878469433.USD","LU2237443465.HKD","BK4139","LU2237443978.SGD","LU0320765646.SGD","LU1162221912.USD","CPK","LU1037948897.HKD","LU2237443622.USD","EC","IE00B42XCP33.USD","IE00BDGV0183.EUR","LU0965508806.USD","LU1551013425.SGD","LU1093756168.USD","LU2087621335.USD","SG9999015978.USD","TAK","LU2023251221.USD","LU2237443895.HKD","BK4559","ABBV","LU0211327993.USD","LU1093756325.SGD","LU1003077747.HKD","RA","IE00B2B36J28.USD","IE0009355771.USD","BK4007","LU0234570918.USD","LU2112291526.USD","SG9999015986.USD","LU0965509101.SGD","LU1061106388.HKD","LU0456855351.SGD","LU2129689431.USD","LU0861579265.USD","ALT","IE0004445239.USD","LU0198837287.USD"],"gpt_icon":0},{"id":"2524610784","title":"Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524610784","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524610784?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:40","pubTimestamp":1743774008,"startTime":"0","endTime":"0","summary":"While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the \"Value\" category. Stocks with high Zacks Ranks and \"A\" grades for Value will be some of the highest-quality value stocks on the market today.One company value investors might notice is Takeda Pharmaceutical Co. . TAK is currently sporting a Zacks","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/takeda-pharmaceutical-co-tak-stock-134008439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2524619262","title":"Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2524619262","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524619262?lang=en_us&edition=fundamental","pubTime":"2025-04-03 22:49","pubTimestamp":1743691747,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts fell Thursday morning, plummeting 4.2% to 2,069.8 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by online education platform 51Talk Online Education Group  and mobile app developer Cheetah Mobile , which rose 2.2% and 1.7% respectively. They were followed by pharmaceutical company Takeda Pharmaceutical  and ad agency 36Kr , which were up 1.6% and 0.9% respectively.The decliners from North Asia were led by computer hardware maker Canaan  and semiconductor company Himax Technologies , which fell 10.5% and 9.8% respectively. They were followed by internet and data center services provider VNET Group  and financial services company Sumitomo Mitsui Financial Group , which dropped 9.2% and 8.8% respectively.From South Asia, the only gainers were pharmaceutical company Dr. Reddy's Laboratories  and financial services company HDFC Bank , which were up 0.6% and 0.5% respectively.The decliners from South Asia we","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4554","IE0034224299.USD","LU0868486357.SGD","HDB","RDY.AU","LU0264606111.USD","CAN","BK4503","LU1102505762.USD","SG9999014484.SGD","BK4595","AFG","LU1048588211.SGD","LU1242518931.SGD","BK4533","LU0791590937.USD","COE","CMCM","LU0532188223.SGD","RDY","SG9999005177.SGD","CAN.AU","SE","BK4007","SIFY","BK4607","WIT","LU0536402901.SGD","SMFG","SG9999006266.SGD","SG9999002679.SGD","LU1267930656.SGD","SG9999013460.SGD","LU0862451753.SGD","LU1791710582.SGD","LU2125910500.SGD","INFY","LU2663582299.SGD","SG9999014021.USD","KRKR","HIMX","BK4548","LU0499858602.USD","LU0516422952.EUR","VNET","SG9999001135.SGD","LU0541501648.USD","LU0630378692.HKD","TAK","BK4551"],"gpt_icon":1},{"id":"2522309065","title":"Takeda Canada says Health Canada expands marketing authorization for HyQvia","url":"https://stock-news.laohu8.com/highlight/detail?id=2522309065","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522309065?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:41","pubTimestamp":1743082866,"startTime":"0","endTime":"0","summary":"Takeda (TAK) Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating polyneu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-canada-says-health-canada-expands-marketing-authorization-for-hyqvia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-canada-says-health-canada-expands-marketing-authorization-for-hyqvia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2522456309","title":"Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus","url":"https://stock-news.laohu8.com/highlight/detail?id=2522456309","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522456309?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:39","pubTimestamp":1743082789,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals  said Thursday that its partner Takeda Pharmaceutical  has received clearance by Japan's Ministry of Health, Labour, and Welfare for Livmarli oral solution to treat cholestatic pruritus in people with Alagille syndrome and progressive familial intrahepatic cholestasis.Mirum said the company and Takeda signed an exclusive licensing deal in September 2021 for the development and commercialization of Livmarli for rare cholestatic pediatric liver diseases in Japan.Under the terms of the deal, Mirum is eligible to get a percentage of Takeda's annual net sales, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TAK","BK4007","BK4139","MIRM"],"gpt_icon":0},{"id":"2522880410","title":"ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522880410","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522880410?lang=en_us&edition=fundamental","pubTime":"2025-03-25 03:00","pubTimestamp":1742842800,"startTime":"0","endTime":"0","summary":"Shares of AC Immune ACIU have lost 18.3% in the past month compared with the industry’s decline of 1.3%. The stock has underperformed the sector and the S&P 500 Index during this timeframe.Earlier in the month, ACIU reported better-than-expected results for the fourth quarter. Nonetheless, shares of this Switzerland-based clinical-stage biopharmaceutical company continue to slide down.Let’s delve deeper and analyze the company’s strengths and weaknesses to understand how to play the stock in such a scenario.ACIU Underperforms Industry, Sector and S&P 500 Index. ACI-7104.056, an active immunotherapy targeting pathological a-syn, is currently being tested in the phase II study  in the EU and the UK.ACIU has collaborated with Janssen Pharmaceuticals, Inc., part of Johnson & Johnson JNJ, for ACI-35.030/JNJ-2056. In September 2024, the company received a milestone payment triggered by the rapid rate of prescreening in the potentially registrational phase IIb ReTain trial and the first patie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aciu-stock-crashes-18-3-190000479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4559","LU1935042991.SGD","BK4581","PD","LU1674673428.USD","ACIU","LU1732799900.SGD","BK4550","IE0002270589.USD","LU2129689514.USD","BK4007","LU1059921491.USD","BK4588","LU1674673691.USD","SG9999002232.USD","TAK","LU2430703251.USD","LU0203345920.USD","LU1066051811.HKD","LU0114720955.EUR","LU0889566641.SGD","IE00BGHQF631.EUR","LU2505996509.AUD","LU1023059063.AUD","IE00B42XCP33.USD","LU1066051498.USD","BK4534","SG9999002224.SGD","LU1162221912.USD","LU0882574055.USD","BK4113","IE00BDGV0183.EUR","LU1778281490.HKD","IE00B2B36J28.USD","LU1585245621.USD","LU2468319806.SGD","IE00B4R5TH58.HKD","BK4023","JNJ","LU2430703178.SGD","IE00B3PB1722.GBP","LU0795875169.SGD","ACI","IE0034235303.USD","LU2133065610.SGD","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU1221951046.USD","IE000M9KFDE8.USD"],"gpt_icon":0},{"id":"2520156726","title":"Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2520156726","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520156726?lang=en_us&edition=fundamental","pubTime":"2025-03-19 21:40","pubTimestamp":1742391607,"startTime":"0","endTime":"0","summary":"While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's \"Value\" category. Stocks with both \"A\" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.One company to watch right now is Takeda Pharma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/takeda-pharmaceutical-co-tak-great-134007882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2519880380","title":"TAK or DSNKY: Which Is the Better Value Stock Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519880380","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519880380?lang=en_us&edition=fundamental","pubTime":"2025-03-14 23:40","pubTimestamp":1741966808,"startTime":"0","endTime":"0","summary":"Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co.  and Daiichi Sankyo Co., Ltd. - Sponsored ADR . But which of these two stocks is more attractive to value investors?We'll need to take a closer look to find out.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.Currently, Takeda Pharmaceutical Co. has a Zacks Rank of #2 , while Daiichi Sankyo Co., Ltd. - Sponsored ADR has a Zacks Rank of #3 . Investors should feel comfortable knowing that TAK likely has seen a stronger improvement to its earnings outlook than DSNKY has recently. However, value investors will care about much more than just this.This article originally published on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tak-dsnky-better-value-stock-154008572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TAK","DSNKY","DSKYF","BK4007"],"gpt_icon":0},{"id":"2519386307","title":"Will ADMA Biologics Stock Continue Its Momentum in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519386307","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519386307?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:40","pubTimestamp":1741959600,"startTime":"0","endTime":"0","summary":"ADMA Biologics ADMA put up a phenomenal performance in 2024 and the rally continues in 2025 as well.Last week, ADMA Biologics announced results for its fourth quarter and full-year 2024 and provided a business update. While adjusted earnings per share of 14 cents missed the Zacks Consensus Estimate by a penny, revenues of $118 million beat the consensus estimate of $112 million.Nonetheless, a single quarter’s results are not important for long-term investors. Let's analyze ADMA’s fundamentals in this scenario.The company’s top line currently comprises sales of three FDA-approved products, which are Bivigam , Asceniv  and Nabi-HB .Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body’s immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease.Concurrent with its fourth-quarter results, ADMA upped its financial targets. ADMA now expects to gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-stock-continue-momentum-134000162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GRFS","ADMA","BK4007","BK4139","TAK"],"gpt_icon":0},{"id":"2516772656","title":"Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2516772656","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516772656?lang=en_us&edition=fundamental","pubTime":"2025-03-04 01:01","pubTimestamp":1741021301,"startTime":"0","endTime":"0","summary":"On Monday, Protagonist Therapeutics, Inc.  and Takeda Pharmaceutical Co Ltd  released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.Polycythemia vera isa type of blood cancer. It causes your bone marrow to make too many red blood cells.Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class investigational hepcidin mimetic peptide therapeutic, which has received FDA Orphan Drug and Fast Track designations.The study’s primary endpoint was the proportion of patients achieving a response, which was defined as the absence of phlebotomy eligibility.The first key secondary endpoint, which is the pre-specified primary endpoint for European Union  regulators, was also met, with a mean of 0.5 phlebotomies per patient in the rusfertide arm compared to 1.8 phlebotomies per patient in the placebo arm during weeks 0-32","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/takeda-protagonist-therapeutics-partnered-investigational-170141358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TAK","SSI","BK4007","BK4139","BK4156","PTGX"],"gpt_icon":0},{"id":"2516653268","title":"Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653268","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653268?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:40","pubTimestamp":1741012819,"startTime":"0","endTime":"0","summary":"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's \"Value\" category. Stocks with \"A\" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.One stock to keep an eye on is Takeda Pharmaceutical Co. . TAK is currently sporting a Zacks Rank of #2 , as well as a Value grade of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/value-investors-buy-takeda-pharmaceutical-144019451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ISBC","TAK","BK4211","BK4007"],"gpt_icon":0},{"id":"2516399566","title":"Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera","url":"https://stock-news.laohu8.com/highlight/detail?id=2516399566","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516399566?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:00","pubTimestamp":1741010438,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) and Takeda (TAK) said Monday that a phase 3 study of investigational drug rusfertide as a potential add-on to standard of care treatment for polycythemia vera, a form o","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTGX","BK4139","TAK","BK4007"],"gpt_icon":0},{"id":"2516784687","title":"Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera","url":"https://stock-news.laohu8.com/highlight/detail?id=2516784687","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516784687?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:45","pubTimestamp":1741002300,"startTime":"0","endTime":"0","summary":"Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo. All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes. Rusfertide was generally well tolerated; no new safety findings were observed in the study. \"The positive results of the Phase 3 VERIFY study across the primary and all key secondary endpoints provide compelling evidence of the potential for rusfertide as a first-in-class erythrocytosis-specific agent to address unmet medical needs in patients with PV who are unable to achieve adequate hematocrit control despite standard of care treatments,\" said Arturo Molina, M.D., M.S., Chief Medical Officer of Protagonist. \"We plan to submit additional details of these promising results for presentation at upcoming medical conferences in 2025. We are immensely grateful to the patients, study staff and principal inves","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protagonist-takeda-announce-positive-topline-114500048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1894683264.USD","LU1585245621.USD","JNJ","IE00BDGV0183.EUR","LU0345770308.USD","BK4139","IE000M9KFDE8.USD","LU0640476718.USD","LU2592432038.USD","LU2129689514.USD","LU1778281490.HKD","LU0320765646.SGD","LU0203347892.USD","LU1674673691.USD","LU1506573853.SGD","LU1244550577.SGD","BK4559","LU0889566641.SGD","LU2602419157.SGD","TAK","LU0795875169.SGD","LU0792757196.USD","LU1061106388.HKD","PTGX","LU0345769631.USD","LU1074936037.SGD","LU0289739699.SGD","LU1894683348.USD","LU1244550494.USD","LU1718418525.SGD","BK4581","LU1066051811.HKD","IE00BVYPNW00.USD","LU1032955483.USD","LU0234572021.USD","IE00BGHQF631.EUR","LU0882574055.USD","IE0034235303.USD","LU1935042991.SGD","LU0058720904.USD","LU1929549753.HKD","LU2505996681.GBP","IE00BVYPNV92.GBP","IE0002141913.USD","IE00B19Z3581.USD","LU1059921491.USD","IE00BJJMRZ35.SGD","LU0122379950.USD","LU0466842654.USD"],"gpt_icon":0},{"id":"2514313647","title":"AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2514313647","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514313647?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:00","pubTimestamp":1740726000,"startTime":"0","endTime":"0","summary":"The positive opinion is based on results from the pivotal Phase 3SELECT-GCA trial that evaluated the efficacy and safety ofupadacitinib in adults with giant cell arteritis 1. The primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure, and complete remission, were met1. GCAis an autoimmune disease that causes inflammation of the large and medium cranial arteries, resulting in potentially debilitating symptoms2. NORTH CHICAGO, Ill., Feb. 28, 2025 /PRNewswire/ -- AbbVie  today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use  adopted a positive opinion recommending the approval of upadacitinib for the treatment of adult patients with GCA. The final European Commission decision is expected in the first half of 2025. If approved, upadacitinib would be the first and only oral advanced therapy for adults living with GCA.*Sustained remission is defined as having ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-receives-positive-chmp-opinion-070000671.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-receives-positive-chmp-opinion-070000671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0949170772.SGD","LU2468319806.SGD","SG9999001440.SGD","BK4566","LU1244550221.USD","BK4588","LU0256863902.USD","LU0689472784.USD","BK4534","LU1003077747.HKD","LU1934455863.HKD","CHMP","LU0795875086.SGD","SG9999003800.SGD","BK4599","LU0122379950.USD","LU1037948541.HKD","LU1061106388.HKD","LU1718418525.SGD","BK4197","LU0882574055.USD","LU1878469433.USD","RA","LU2237443895.HKD","LU1989771016.USD","BK4007","LU0114720955.EUR","BK4581","LU0417517546.SGD","LU0661504455.SGD","LU0861579265.USD","IE00BJJMRZ35.SGD","LU0545039389.USD","LU1551013342.USD","LU2237443382.USD","CPK","LU1585245621.USD","ABBV","LU0820561818.USD","LU0198837287.USD","LU1267930573.SGD","LU0553294199.USD","TAK","LU2237443978.SGD","BK4139","ALT","LU0708994859.HKD","LU2347655156.SGD","LU0943347566.SGD"],"gpt_icon":0},{"id":"2514072568","title":"Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514072568","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514072568?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:43","pubTimestamp":1740663800,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now.In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited  stands against the other pharma stocks.The Rising Demand for Weight-Loss Medications and GLP-1 Developments. Competition with the leading companies in the anti-obesity business, which is expected to grow to $130 billion by 2030, is no longer the main emphasis. The possibility for additional participants to enter the field is growing along with the possible applications of GLP-1s. For example, the Swiss business Roche entered the weight-loss drug sweepstakes last year when it paid up to $3.1 billion to acquire California-based Carmot Therapeutics. The corporation wants to \"fast-track\" its anti-obesity medicines to regain faith in its pipeline and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/takeda-pharmaceutical-company-limited-tak-134320152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4609","BK4141","CAGR","BK4588","IE00BMPRXN33.USD","LU0348723411.USD","BK4159","TAK","BK4007","IE00BMPRXR70.SGD","BK4585","BK4543","IE00BMPRXQ63.HKD"],"gpt_icon":1},{"id":"2513749337","title":"Takeda announces EMA approval for Takhzyro two mL pre-filled pen option","url":"https://stock-news.laohu8.com/highlight/detail?id=2513749337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513749337?lang=en_us&edition=fundamental","pubTime":"2025-02-24 18:17","pubTimestamp":1740392278,"startTime":"0","endTime":"0","summary":"Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in adolesc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-announces-ema-approval-for-takhzyro-two-ml-pre-filled-pen-option?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-announces-ema-approval-for-takhzyro-two-ml-pre-filled-pen-option?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2513748308","title":"Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2513748308","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513748308?lang=en_us&edition=fundamental","pubTime":"2025-02-24 17:26","pubTimestamp":1740389214,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Co  said Monday that the European Medicines Agency has approved an additional subcutaneous administration option for hereditary angioedema drug TAKHZYRO, or lanadelumab.The drug now comes in a 2 mL pre-filled pen for adolescent and adult patients, the company said.Hereditary angioedema is a rare genetic disease that causes severe swelling in the body.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2513711489","title":"The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513711489","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513711489?lang=en_us&edition=fundamental","pubTime":"2025-02-24 16:01","pubTimestamp":1740384060,"startTime":"0","endTime":"0","summary":"TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent  and Adult Patients with HAE.1. The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients.In the EU, TAKHZYRO is Approved for Routine Prevention of Recurrent HAE Attacks in Patients Aged 2 Years and Older.1. ZURICH, Feb. 24, 2025 /PRNewswire/ -- Takeda   announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO  for subcutaneous administration in adolescents  and adult patients with Hereditary Angioedema .1. The additional subcutaneous administration option expands Takeda's offering in this space, showing dedication to the HAE community while providing individualized treatment options to support patients with a life-threatening disease, by helping to reduce HAE burden and improving their Quality of Life.\"HAE affects an estimated 1 in 50,000 people worldwide","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/european-medicines-agency-ema-approved-080100583.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-medicines-agency-ema-approved-080100583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0205194284.USD","LU0205193047.USD","IE00BLDYK493.USD","LU0106261612.USD","IE00B64QTZ34.USD","BK4007","HAE","LU1169590202.USD","TAK","LU1169589451.USD","MDCO","BK4198","LU0012050646.USD"],"gpt_icon":0},{"id":"2512922084","title":"TAK vs. DSNKY: Which Stock Is the Better Value Option?","url":"https://stock-news.laohu8.com/highlight/detail?id=2512922084","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512922084?lang=en_us&edition=fundamental","pubTime":"2025-02-18 00:40","pubTimestamp":1739810413,"startTime":"0","endTime":"0","summary":"Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co.  and Daiichi Sankyo Co., Ltd. - Sponsored ADR . But which of these two stocks is more attractive to value investors?We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.Takeda Pharmaceutical Co. and Daiichi Sankyo Co., Ltd. - Sponsored ADR are sporting Zacks Ranks of #2  and #3 , respectively, right now. Investors should feel comfortable knowing that TAK likely has seen a stronger improvement to its earnings outlook than DSNKY has recently. However, value investors will care about much more than just this.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tak-vs-dsnky-stock-better-164013572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TAK","BK4007","DSKYF","DSNKY"],"gpt_icon":0},{"id":"2511609700","title":"Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511609700","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511609700?lang=en_us&edition=fundamental","pubTime":"2025-02-16 03:43","pubTimestamp":1739648612,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Japanese Stocks To Buy in 2025.In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited  stands against the other Japanese stocks.The current environment around Japanese markets is one of concern and relief, especially after U.S. President Donald Trump announced tariffs on steel and aluminum imports. Trump's threats to impose retaliatory tariffs on \"everyone\" have served as a harsh reminder of the dangers that all of America's trading partners, including Japan, face. With Trump aiming to reduce his country's trade imbalance with Japan, Japanese Prime Minister Shigeru Ishiba pledged to purchase more American LNG and disclosed plans for manufacturers such as Toyota and Isuzu Motors to invest more in the United States at their summit meeting on February 7. Homin Lee, senior macro strategist at Lombard Odier in Sing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/takeda-pharmaceutical-company-limited-tak-194332882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","TAK"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":86,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TAK\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-30","symbol":"TAK","fiscalQuarterEnding":"2024/12","expectedEps":0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1738213200000,"reportTimeType":"pre","actualEps":0.42},{"market":"US","date":"2024-10-31","symbol":"TAK","fiscalQuarterEnding":"2024/09","expectedEps":0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730347200000,"reportTimeType":"pre","actualEps":0.44},{"market":"US","date":"2024-07-31","symbol":"TAK","fiscalQuarterEnding":"2024/06","expectedEps":0.37,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1722398400000,"reportTimeType":"pre","actualEps":0.56},{"market":"US","date":"2024-05-09","symbol":"TAK","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":0},{"market":"US","date":"2024-02-01","symbol":"TAK","fiscalQuarterEnding":"2023/12","expectedEps":0.37,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"pre","actualEps":0.51}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TAK\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TAK\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1689480000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TAK\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TAK","date":"2025-05-12","current":58.311754,"percent":0.900243,"low":9.919003,"twenty":15.728527,"median":29.784868,"eighty":44.978649,"high":446.289928,"avg":37.234233,"sd":31.898903,"marketCap":42498183485.5},"quantilePoints":[{"date":"2020-05-15","current":141.266146,"twenty":25.78995,"median":36.47458,"eighty":82.305276,"marketCap":58229887273.26},{"date":"2020-05-22","current":142.498528,"twenty":25.895823,"median":36.514941,"eighty":82.473666,"marketCap":58640622164.25},{"date":"2020-05-29","current":147.568898,"twenty":26.094305,"median":36.5454,"eighty":82.720638,"marketCap":60618343666.07},{"date":"2020-06-05","current":142.287262,"twenty":26.802799,"median":36.578836,"eighty":82.960126,"marketCap":57369545717.84},{"date":"2020-06-12","current":140.456295,"twenty":26.987384,"median":36.601121,"eighty":83.356777,"marketCap":57891751795.22},{"date":"2020-06-19","current":141.688677,"twenty":27.833349,"median":36.617455,"eighty":83.603749,"marketCap":58614309903.35},{"date":"2020-06-26","current":139.787288,"twenty":28.382494,"median":36.66065,"eighty":84.02269,"marketCap":57689640075.75},{"date":"2020-07-02","current":134.083122,"twenty":28.490627,"median":36.703774,"eighty":84.187418,"marketCap":55151885879.75},{"date":"2020-07-10","current":129.224017,"twenty":28.584436,"median":36.784141,"eighty":85.31532,"marketCap":53543496364.44},{"date":"2020-07-17","current":130.667664,"twenty":28.683495,"median":36.800541,"eighty":86.385434,"marketCap":53972328180.49},{"date":"2020-07-24","current":133.164486,"twenty":28.804715,"median":36.81694,"eighty":87.725687,"marketCap":55658397179.21},{"date":"2020-07-31","current":49.030087,"twenty":28.880318,"median":36.830882,"eighty":88.33002,"marketCap":55557224542.23},{"date":"2020-08-07","current":49.695831,"twenty":29.000288,"median":36.883572,"eighty":88.247168,"marketCap":56220621340.2},{"date":"2020-08-14","current":51.954139,"twenty":29.120238,"median":36.973174,"eighty":88.149695,"marketCap":58424376584.77},{"date":"2020-08-21","current":52.698206,"twenty":29.210125,"median":37.019329,"eighty":87.725687,"marketCap":59589605364.98},{"date":"2020-08-28","current":51.875816,"twenty":29.296114,"median":37.194931,"eighty":87.39428,"marketCap":59006258563.45},{"date":"2020-09-04","current":50.217983,"twenty":29.358735,"median":37.349685,"eighty":86.853304,"marketCap":56544754820.4},{"date":"2020-09-11","current":51.079534,"twenty":29.413482,"median":37.496711,"eighty":86.502401,"marketCap":57600970548.14},{"date":"2020-09-18","current":52.071623,"twenty":29.482546,"median":37.644832,"eighty":86.409802,"marketCap":59718536367.45},{"date":"2020-09-25","current":51.23618,"twenty":29.528429,"median":37.70687,"eighty":86.307455,"marketCap":58079537631.11},{"date":"2020-10-02","current":47.267823,"twenty":29.55872,"median":37.818162,"eighty":86.127131,"marketCap":53733241411.92},{"date":"2020-10-09","current":48.45572,"twenty":29.570204,"median":38.056274,"eighty":85.695464,"marketCap":54928745380.19},{"date":"2020-10-16","current":45.740528,"twenty":29.581756,"median":38.101028,"eighty":85.328548,"marketCap":51955606617.4},{"date":"2020-10-23","current":45.688313,"twenty":29.610527,"median":38.151519,"eighty":85.068348,"marketCap":52213782354.12},{"date":"2020-10-30","current":90.341121,"twenty":29.668895,"median":38.172466,"eighty":85.328548,"marketCap":48419952386.27},{"date":"2020-11-06","current":96.588856,"twenty":29.692357,"median":38.217233,"eighty":86.409802,"marketCap":52398853598.67},{"date":"2020-11-13","current":100.410015,"twenty":29.692593,"median":38.315348,"eighty":87.847529,"marketCap":53780559103.29},{"date":"2020-11-20","current":101.776706,"twenty":29.697927,"median":38.413443,"eighty":88.520092,"marketCap":54951029488.93},{"date":"2020-11-27","current":104.091715,"twenty":29.726253,"median":38.431569,"eighty":89.212151,"marketCap":56090722051.49},{"date":"2020-12-04","current":108.749624,"twenty":29.809673,"median":41.476727,"eighty":89.840851,"marketCap":58500568009.94},{"date":"2020-12-11","current":107.940766,"twenty":29.825396,"median":42.195512,"eighty":90.113776,"marketCap":58227511975.44},{"date":"2020-12-18","current":108.136007,"twenty":29.898634,"median":42.406568,"eighty":90.568631,"marketCap":58641544051.05},{"date":"2020-12-24","current":104.063823,"twenty":29.940017,"median":42.671516,"eighty":90.966664,"marketCap":56275869966.77},{"date":"2020-12-31","current":104.733224,"twenty":29.971299,"median":42.851076,"eighty":91.332188,"marketCap":56879881356.69},{"date":"2021-01-08","current":103.059723,"twenty":29.97912,"median":42.920583,"eighty":91.791488,"marketCap":55589135003.46},{"date":"2021-01-15","current":100.437906,"twenty":29.989622,"median":43.181235,"eighty":92.111972,"marketCap":54236546808.57},{"date":"2021-01-22","current":100.047423,"twenty":30.031602,"median":43.418717,"eighty":92.258181,"marketCap":54029329143.49},{"date":"2021-01-29","current":103.143398,"twenty":30.073173,"median":43.598578,"eighty":92.394644,"marketCap":55216620705.7},{"date":"2021-02-05","current":31.781037,"twenty":30.157692,"median":43.665039,"eighty":92.535979,"marketCap":54432227223.55},{"date":"2021-02-12","current":31.919516,"twenty":30.223066,"median":43.441886,"eighty":92.526232,"marketCap":54935581599.54},{"date":"2021-02-19","current":31.997411,"twenty":30.238705,"median":43.337626,"eighty":92.438506,"marketCap":54757645997.71},{"date":"2021-02-26","current":31.00209,"twenty":30.269781,"median":42.961129,"eighty":92.297171,"marketCap":52506642547.95},{"date":"2021-03-05","current":32.525364,"twenty":30.307584,"median":42.874245,"eighty":92.272802,"marketCap":54273339139.55},{"date":"2021-03-12","current":34.741035,"twenty":30.314105,"median":42.671516,"eighty":92.258181,"marketCap":57572160306.5},{"date":"2021-03-19","current":36.991326,"twenty":30.320622,"median":42.376112,"eighty":92.258181,"marketCap":61377881020.81},{"date":"2021-03-26","current":36.385479,"twenty":30.34278,"median":42.069006,"eighty":92.219192,"marketCap":59972674222.12},{"date":"2021-04-01","current":35.38287,"twenty":30.371454,"median":41.476727,"eighty":92.150961,"marketCap":57783874962.89},{"date":"2021-04-09","current":32.481215,"twenty":30.393667,"median":38.431569,"eighty":92.111972,"marketCap":53478879478.89},{"date":"2021-04-16","current":32.082779,"twenty":30.470959,"median":38.377853,"eighty":92.111972,"marketCap":53250001858.4},{"date":"2021-04-23","current":31.900884,"twenty":30.513064,"median":38.294386,"eighty":92.058362,"marketCap":53341682665.94},{"date":"2021-04-30","current":31.485125,"twenty":30.533079,"median":38.21414,"eighty":91.833434,"marketCap":52029509066.16},{"date":"2021-05-07","current":31.831591,"twenty":30.534382,"median":38.169603,"eighty":91.791488,"marketCap":52970833572.63},{"date":"2021-05-14","current":15.564762,"twenty":30.470959,"median":38.145677,"eighty":91.758112,"marketCap":53496176267.97},{"date":"2021-05-21","current":15.876889,"twenty":30.319318,"median":38.091991,"eighty":91.609986,"marketCap":54795356598.76},{"date":"2021-05-28","current":15.664642,"twenty":30.236167,"median":38.041392,"eighty":91.546628,"marketCap":53587690959.61},{"date":"2021-06-04","current":15.281766,"twenty":30.057838,"median":37.818162,"eighty":91.527134,"marketCap":52499044333.6},{"date":"2021-06-11","current":15.732274,"twenty":29.940017,"median":37.70687,"eighty":91.283451,"marketCap":53886220157.49},{"date":"2021-06-18","current":15.499142,"twenty":29.705398,"median":37.644832,"eighty":91.259083,"marketCap":52855138856.99},{"date":"2021-06-25","current":15.64495,"twenty":29.653254,"median":37.496711,"eighty":91.185978,"marketCap":53110087882.29},{"date":"2021-07-02","current":15.624135,"twenty":29.556114,"median":37.309512,"eighty":90.966664,"marketCap":52790633079.89},{"date":"2021-07-09","current":15.170356,"twenty":29.369182,"median":37.239049,"eighty":90.713234,"marketCap":51765371608.86},{"date":"2021-07-16","current":15.553362,"twenty":29.036801,"median":37.034171,"eighty":90.649877,"marketCap":53089153550.44},{"date":"2021-07-23","current":15.445121,"twenty":28.610503,"median":36.990446,"eighty":90.630383,"marketCap":52540828243.5},{"date":"2021-07-30","current":13.400212,"twenty":26.987384,"median":36.968687,"eighty":90.397999,"marketCap":52641482781.37},{"date":"2021-08-06","current":13.231512,"twenty":25.788836,"median":36.881192,"eighty":90.295707,"marketCap":51739766156.6},{"date":"2021-08-13","current":13.399277,"twenty":25.542527,"median":36.851251,"eighty":90.284353,"marketCap":52624385513.69},{"date":"2021-08-20","current":13.340924,"twenty":25.375364,"median":36.822486,"eighty":90.167386,"marketCap":52391869685.63},{"date":"2021-08-27","current":13.304453,"twenty":25.07978,"median":36.81694,"eighty":90.040671,"marketCap":52184954198.97},{"date":"2021-09-03","current":13.585277,"twenty":24.895379,"median":36.800541,"eighty":89.938325,"marketCap":53414238064.1},{"date":"2021-09-10","current":13.6801,"twenty":24.732641,"median":36.787118,"eighty":89.91883,"marketCap":53684261064.92},{"date":"2021-09-17","current":13.906217,"twenty":24.583535,"median":36.72461,"eighty":89.874967,"marketCap":54565644835.19},{"date":"2021-09-24","current":13.753041,"twenty":24.444102,"median":36.66065,"eighty":89.831104,"marketCap":53563443001.25},{"date":"2021-10-01","current":13.260689,"twenty":24.187434,"median":36.617455,"eighty":89.777494,"marketCap":51482210756.95},{"date":"2021-10-08","current":11.666926,"twenty":23.93319,"median":36.601121,"eighty":89.748252,"marketCap":44862900501.13},{"date":"2021-10-15","current":11.787279,"twenty":23.7033,"median":36.578836,"eighty":89.499696,"marketCap":44516597060.99},{"date":"2021-10-22","current":11.681514,"twenty":23.539863,"median":36.5454,"eighty":88.968468,"marketCap":44293684279.19},{"date":"2021-10-29","current":10.648321,"twenty":23.423498,"median":36.488155,"eighty":88.710165,"marketCap":44164269191.12},{"date":"2021-11-05","current":10.784625,"twenty":23.226892,"median":36.468627,"eighty":88.627312,"marketCap":44983557825.66},{"date":"2021-11-12","current":10.950849,"twenty":22.951173,"median":36.398869,"eighty":88.490851,"marketCap":45493195113.2},{"date":"2021-11-19","current":10.728109,"twenty":22.593579,"median":36.365388,"eighty":88.33002,"marketCap":44596449686.83},{"date":"2021-11-26","current":10.425581,"twenty":22.055183,"median":36.25968,"eighty":88.252042,"marketCap":43512424769.26},{"date":"2021-12-03","current":10.106651,"twenty":21.515452,"median":36.172679,"eighty":88.178937,"marketCap":42286529642.36},{"date":"2021-12-10","current":10.142864,"twenty":21.321368,"median":36.088488,"eighty":87.847529,"marketCap":42348534488.31},{"date":"2021-12-17","current":10.34424,"twenty":21.015505,"median":36.02197,"eighty":87.423521,"marketCap":43082485607.36},{"date":"2021-12-23","current":10.363994,"twenty":20.795645,"median":35.82744,"eighty":87.174965,"marketCap":42874132957.12},{"date":"2021-12-31","current":10.327779,"twenty":20.657578,"median":35.632629,"eighty":86.517022,"marketCap":42437110052.52},{"date":"2022-01-07","current":10.522022,"twenty":20.640925,"median":35.562823,"eighty":86.434171,"marketCap":43033429977.32},{"date":"2022-01-14","current":11.009273,"twenty":20.536864,"median":35.556871,"eighty":86.322076,"marketCap":45750368973.66},{"date":"2022-01-21","current":10.940136,"twenty":20.171308,"median":35.520843,"eighty":86.263593,"marketCap":45488233052.08},{"date":"2022-01-28","current":10.953305,"twenty":19.949589,"median":35.455688,"eighty":85.922437,"marketCap":44994125510.56},{"date":"2022-02-04","current":12.019761,"twenty":19.86233,"median":35.393845,"eighty":85.355005,"marketCap":45736794370.02},{"date":"2022-02-11","current":12.502153,"twenty":19.831282,"median":35.308236,"eighty":85.302091,"marketCap":47298200126.65},{"date":"2022-02-18","current":12.558981,"twenty":19.671006,"median":35.308236,"eighty":85.302091,"marketCap":47834673171.52},{"date":"2022-02-25","current":12.196703,"twenty":19.550551,"median":35.308236,"eighty":85.302091,"marketCap":46263555485.74},{"date":"2022-03-04","current":12.289048,"twenty":19.380891,"median":35.308236,"eighty":85.302091,"marketCap":46976698663.99},{"date":"2022-03-11","current":12.043978,"twenty":19.117196,"median":35.308236,"eighty":85.302091,"marketCap":45095629553.81},{"date":"2022-03-18","current":12.707196,"twenty":18.980245,"median":35.308236,"eighty":85.302091,"marketCap":46769031069.82},{"date":"2022-03-25","current":12.770838,"twenty":18.858799,"median":35.308236,"eighty":85.302091,"marketCap":45895036970.15},{"date":"2022-04-01","current":12.530413,"twenty":18.69121,"median":35.308236,"eighty":85.302091,"marketCap":44742437445.66},{"date":"2022-04-08","current":13.064299,"twenty":18.623126,"median":35.308236,"eighty":85.302091,"marketCap":46073289723.14},{"date":"2022-04-14","current":13.294114,"twenty":18.443795,"median":35.308236,"eighty":85.302091,"marketCap":46294767383.12},{"date":"2022-04-22","current":13.21633,"twenty":18.221438,"median":35.308236,"eighty":85.302091,"marketCap":45025239824.55},{"date":"2022-04-29","current":13.325935,"twenty":17.979017,"median":35.308236,"eighty":85.302091,"marketCap":45022632781.95},{"date":"2022-05-06","current":13.53454,"twenty":17.700642,"median":35.308236,"eighty":85.302091,"marketCap":45566277364},{"date":"2022-05-13","current":24.629857,"twenty":15.872727,"median":35.308236,"eighty":85.302091,"marketCap":43848144051.53},{"date":"2022-05-20","current":25.018997,"twenty":15.872727,"median":35.308236,"eighty":85.302091,"marketCap":45016426783.75},{"date":"2022-05-27","current":25.119636,"twenty":15.872727,"median":35.308236,"eighty":85.302091,"marketCap":45470626890.48},{"date":"2022-06-03","current":24.280973,"twenty":15.872727,"median":35.308236,"eighty":85.302091,"marketCap":42728413394.89},{"date":"2022-06-10","current":24.368194,"twenty":15.872727,"median":35.308236,"eighty":85.302091,"marketCap":41777808638.38},{"date":"2022-06-17","current":23.83145,"twenty":15.872727,"median":35.308236,"eighty":85.302091,"marketCap":40560767412.66},{"date":"2022-06-24","current":24.871564,"twenty":15.868566,"median":35.321487,"eighty":85.31532,"marketCap":42352646298.73},{"date":"2022-07-01","current":25.220478,"twenty":15.868566,"median":35.321487,"eighty":85.31532,"marketCap":42911856821.29},{"date":"2022-07-08","current":26.059148,"twenty":15.868566,"median":35.321487,"eighty":85.31532,"marketCap":44046297256.04},{"date":"2022-07-15","current":26.763631,"twenty":15.868566,"median":35.321487,"eighty":85.31532,"marketCap":44459950529.79},{"date":"2022-07-22","current":26.817305,"twenty":15.868566,"median":35.321487,"eighty":85.31532,"marketCap":45321441244.41},{"date":"2022-07-29","current":30.743571,"twenty":15.868566,"median":35.321487,"eighty":85.31532,"marketCap":45477961048.28},{"date":"2022-08-05","current":29.247514,"twenty":15.868566,"median":35.251678,"eighty":85.31532,"marketCap":42639852719.36},{"date":"2022-08-12","current":29.748811,"twenty":15.868566,"median":35.071486,"eighty":85.31532,"marketCap":43951767417.68},{"date":"2022-08-19","current":29.8898,"twenty":15.868566,"median":34.741035,"eighty":85.31532,"marketCap":43038704613},{"date":"2022-08-26","current":29.874135,"twenty":15.868566,"median":33.797644,"eighty":85.31532,"marketCap":42969756201.7},{"date":"2022-09-02","current":30.022957,"twenty":15.868566,"median":32.525364,"eighty":85.31532,"marketCap":42304023842.38},{"date":"2022-09-09","current":30.65741,"twenty":15.868566,"median":32.307982,"eighty":85.31532,"marketCap":42457872052.31},{"date":"2022-09-16","current":30.406762,"twenty":15.868566,"median":32.13589,"eighty":85.31532,"marketCap":41975860478.2},{"date":"2022-09-23","current":29.784868,"twenty":15.868566,"median":32.082779,"eighty":85.31532,"marketCap":41053322910.74},{"date":"2022-09-30","current":29.611929,"twenty":15.868566,"median":31.991351,"eighty":85.31532,"marketCap":40398024705.55},{"date":"2022-10-07","current":29.784868,"twenty":15.868566,"median":31.910861,"eighty":85.31532,"marketCap":40490115913.28},{"date":"2022-10-14","current":30.091442,"twenty":15.868566,"median":31.822929,"eighty":85.31532,"marketCap":40007811364.69},{"date":"2022-10-21","current":29.234607,"twenty":15.868566,"median":31.680102,"eighty":85.31532,"marketCap":38943108088.84},{"date":"2022-10-28","current":27.96678,"twenty":15.868566,"median":31.562866,"eighty":85.31532,"marketCap":40412932074.34},{"date":"2022-11-04","current":27.990228,"twenty":15.868566,"median":31.51076,"eighty":85.31532,"marketCap":40544936411.09},{"date":"2022-11-11","current":28.209015,"twenty":15.868566,"median":31.374814,"eighty":85.31532,"marketCap":43206259311.05},{"date":"2022-11-18","current":28.704934,"twenty":15.868566,"median":31.254645,"eighty":85.31532,"marketCap":43730486647.27},{"date":"2022-11-25","current":29.426933,"twenty":15.868566,"median":31.201154,"eighty":85.31532,"marketCap":45057111010.77},{"date":"2022-12-02","current":28.931014,"twenty":15.868566,"median":31.037761,"eighty":85.31532,"marketCap":45570767384.44},{"date":"2022-12-09","current":29.835336,"twenty":15.868566,"median":30.937343,"eighty":85.31532,"marketCap":46637499358.3},{"date":"2022-12-16","current":30.331255,"twenty":15.868566,"median":30.871973,"eighty":85.31532,"marketCap":47313819017.43},{"date":"2022-12-23","current":29.900973,"twenty":15.868566,"median":30.772934,"eighty":85.31532,"marketCap":47996239753.01},{"date":"2022-12-30","current":29.981195,"twenty":15.868566,"median":30.71556,"eighty":85.31532,"marketCap":48463304453.77},{"date":"2023-01-06","current":29.755114,"twenty":15.868566,"median":30.572454,"eighty":85.31532,"marketCap":47870974965.36},{"date":"2023-01-13","current":29.864508,"twenty":15.868566,"median":30.484406,"eighty":85.31532,"marketCap":49882681588.13},{"date":"2023-01-20","current":30.426063,"twenty":15.868566,"median":30.426063,"eighty":85.31532,"marketCap":49943652563.58},{"date":"2023-01-27","current":30.148932,"twenty":15.868566,"median":30.406762,"eighty":85.31532,"marketCap":49467797966.47},{"date":"2023-02-03","current":23.618692,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":49524315647.28},{"date":"2023-02-10","current":23.884908,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":49885153889.85},{"date":"2023-02-17","current":23.681054,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":48373362782.36},{"date":"2023-02-24","current":23.799969,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":47942402215.74},{"date":"2023-03-03","current":24.043461,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":48450666632.88},{"date":"2023-03-10","current":24.621048,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50074775527.78},{"date":"2023-03-17","current":24.802252,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":51520828536.51},{"date":"2023-03-24","current":24.139732,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50698940566.02},{"date":"2023-03-31","current":24.63238,"twenty":15.872727,"median":30.373407,"eighty":85.302091,"marketCap":50868882296.85},{"date":"2023-04-06","current":24.898523,"twenty":15.872727,"median":30.373407,"eighty":85.302091,"marketCap":51908951328.51},{"date":"2023-04-14","current":25.289243,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":52430478946.56},{"date":"2023-04-21","current":25.436471,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":52090554629.18},{"date":"2023-04-28","current":25.549723,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":52360758781.69},{"date":"2023-05-05","current":25.934781,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":53114594501.1},{"date":"2023-05-12","current":21.816188,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":51463307525.88},{"date":"2023-05-19","current":21.919152,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50148262100.11},{"date":"2023-05-26","current":22.174322,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50264110513.18},{"date":"2023-06-02","current":21.909524,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50016322403.86},{"date":"2023-06-09","current":22.247876,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50740318667.02},{"date":"2023-06-16","current":22.419504,"twenty":15.868566,"median":30.376663,"eighty":85.31532,"marketCap":50575421543.16},{"date":"2023-06-23","current":22.547244,"twenty":15.864404,"median":30.386777,"eighty":85.328548,"marketCap":50034367985.85},{"date":"2023-06-30","current":22.199081,"twenty":15.864404,"median":30.386777,"eighty":85.328548,"marketCap":48652831553.96},{"date":"2023-07-07","current":21.625347,"twenty":15.864404,"median":30.386777,"eighty":85.328548,"marketCap":47542321682.04},{"date":"2023-07-14","current":21.105555,"twenty":15.864404,"median":30.386777,"eighty":85.328548,"marketCap":48436114801.39},{"date":"2023-07-21","current":21.512562,"twenty":15.864404,"median":30.386777,"eighty":85.328548,"marketCap":48597606707.51},{"date":"2023-07-28","current":22.302484,"twenty":15.864404,"median":30.386777,"eighty":85.328548,"marketCap":47655983749.28},{"date":"2023-08-04","current":22.405905,"twenty":15.864404,"median":30.349157,"eighty":85.328548,"marketCap":47472091400.73},{"date":"2023-08-11","current":22.962958,"twenty":15.864404,"median":30.308236,"eighty":85.328548,"marketCap":47925971293.26},{"date":"2023-08-18","current":22.653484,"twenty":15.864404,"median":30.308236,"eighty":85.328548,"marketCap":46744998549.67},{"date":"2023-08-25","current":22.947484,"twenty":15.864404,"median":30.308236,"eighty":85.328548,"marketCap":47472892956.93},{"date":"2023-09-01","current":23.262116,"twenty":15.864404,"median":30.265696,"eighty":85.328548,"marketCap":48142626644.03},{"date":"2023-09-08","current":23.262116,"twenty":15.864404,"median":30.265696,"eighty":85.328548,"marketCap":47619131084.19},{"date":"2023-09-15","current":25.06738,"twenty":15.864404,"median":30.239629,"eighty":85.328548,"marketCap":51339735089.9},{"date":"2023-09-22","current":24.298853,"twenty":15.864404,"median":30.152523,"eighty":85.328548,"marketCap":49671905160.78},{"date":"2023-09-29","current":23.9378,"twenty":15.864404,"median":30.101284,"eighty":85.328548,"marketCap":48306094881.06},{"date":"2023-10-06","current":23.12801,"twenty":15.864404,"median":30.064639,"eighty":85.328548,"marketCap":46912236069.61},{"date":"2023-10-13","current":23.4478,"twenty":15.864404,"median":30.064639,"eighty":85.328548,"marketCap":47185225879.19},{"date":"2023-10-20","current":22.447168,"twenty":15.864404,"median":30.035164,"eighty":85.328548,"marketCap":45133632614.81},{"date":"2023-10-27","current":33.018744,"twenty":15.848805,"median":30.061417,"eighty":85.468491,"marketCap":42045438777.36},{"date":"2023-11-03","current":33.977052,"twenty":15.848805,"median":30.109117,"eighty":85.468491,"marketCap":43262280273.82},{"date":"2023-11-10","current":34.001614,"twenty":15.848805,"median":30.156114,"eighty":85.468491,"marketCap":43146195810.29},{"date":"2023-11-17","current":34.509223,"twenty":15.848805,"median":30.265619,"eighty":85.468491,"marketCap":43924997173.45},{"date":"2023-11-24","current":34.411351,"twenty":15.848805,"median":30.338548,"eighty":85.468491,"marketCap":44071202551.42},{"date":"2023-12-01","current":34.149357,"twenty":15.848805,"median":30.406762,"eighty":85.468491,"marketCap":44271809028.5},{"date":"2023-12-08","current":33.224188,"twenty":15.856081,"median":30.46982,"eighty":85.355005,"marketCap":44164475676.92},{"date":"2023-12-15","current":32.708387,"twenty":15.856081,"median":30.676992,"eighty":85.355005,"marketCap":44261463171.18},{"date":"2023-12-22","current":32.732997,"twenty":15.856081,"median":31.207345,"eighty":85.355005,"marketCap":44132705649.12},{"date":"2023-12-29","current":33.191488,"twenty":15.848805,"median":31.270394,"eighty":85.468491,"marketCap":45078827041.22},{"date":"2024-01-05","current":35.107326,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":46553386498.52},{"date":"2024-01-12","current":35.467569,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":46529118760.4},{"date":"2024-01-19","current":35.574004,"twenty":15.834252,"median":31.485125,"eighty":85.695464,"marketCap":46054562134.98},{"date":"2024-01-26","current":35.287452,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":45813893702.51},{"date":"2024-02-02","current":37.669312,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":45919514328.61},{"date":"2024-02-09","current":37.493246,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":44733412617.38},{"date":"2024-02-16","current":38.84015,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":46075141205.13},{"date":"2024-02-23","current":39.033823,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":46211688108.13},{"date":"2024-03-01","current":38.637675,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":45954550562.52},{"date":"2024-03-08","current":38.311953,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":46140815426.08},{"date":"2024-03-15","current":37.871788,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":45561442683.96},{"date":"2024-03-22","current":38.796134,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":45585981704.56},{"date":"2024-03-28","current":37.000261,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":43584427473.65},{"date":"2024-04-05","current":36.269795,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":42616375994.67},{"date":"2024-04-12","current":36.498683,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":42430179712.64},{"date":"2024-04-19","current":35.820825,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":41294416133.79},{"date":"2024-04-26","current":35.997119,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":41249770241.05},{"date":"2024-05-03","current":36.314041,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":42076379836.26},{"date":"2024-05-10","current":36.349255,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":41627594417.07},{"date":"2024-05-17","current":44.976968,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":41733682877.63},{"date":"2024-05-24","current":45.020529,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":41285104836.56},{"date":"2024-05-31","current":45.445251,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":41787899615.91},{"date":"2024-06-07","current":46.087779,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":42554175847.16},{"date":"2024-06-14","current":45.107651,"twenty":15.848805,"median":31.485125,"eighty":85.468491,"marketCap":41415614115.37},{"date":"2024-06-21","current":43.866156,"twenty":15.841528,"median":31.485125,"eighty":85.581978,"marketCap":39824219396.61},{"date":"2024-06-28","current":45.436656,"twenty":15.818034,"median":31.394177,"eighty":85.990668,"marketCap":40737102327.33},{"date":"2024-07-05","current":46.209907,"twenty":15.818034,"median":31.394177,"eighty":85.990668,"marketCap":41309547172.12},{"date":"2024-07-12","current":47.281654,"twenty":15.818034,"median":31.394177,"eighty":85.990668,"marketCap":42963991363.06},{"date":"2024-07-15","current":47.281654,"twenty":15.818034,"median":31.394177,"eighty":85.990668,"marketCap":43152064633.5},{"date":"2024-08-02","current":44.272889,"twenty":15.741453,"median":31.201154,"eighty":86.195362,"marketCap":44210960292.65},{"date":"2024-08-09","current":43.014896,"twenty":15.741453,"median":31.201154,"eighty":84.363274,"marketCap":43794562967.78},{"date":"2024-08-16","current":45.710595,"twenty":15.741453,"median":31.201154,"eighty":83.962818,"marketCap":46020941359.68},{"date":"2024-08-23","current":46.418876,"twenty":15.741453,"median":31.201154,"eighty":83.592523,"marketCap":47626372624.72},{"date":"2024-08-30","current":45.805737,"twenty":15.741453,"median":31.201154,"eighty":83.199613,"marketCap":47269997055.1},{"date":"2024-09-06","current":45.150312,"twenty":15.741453,"median":31.201154,"eighty":82.795478,"marketCap":47112822724.29},{"date":"2024-09-13","current":43.733749,"twenty":15.741453,"median":31.201154,"eighty":82.469924,"marketCap":46054603558.91},{"date":"2024-09-20","current":45.192598,"twenty":15.741453,"median":31.201154,"eighty":82.039594,"marketCap":47462516587.04},{"date":"2024-09-27","current":44.008604,"twenty":15.741453,"median":31.201154,"eighty":81.796364,"marketCap":45577615083.94},{"date":"2024-10-04","current":44.8226,"twenty":15.741453,"median":31.201154,"eighty":81.650426,"marketCap":45789892958.1},{"date":"2024-10-11","current":45.034027,"twenty":15.741453,"median":31.201154,"eighty":81.051706,"marketCap":45471085814.96},{"date":"2024-10-18","current":45.203169,"twenty":15.741453,"median":31.201154,"eighty":80.673764,"marketCap":45181771588.11},{"date":"2024-10-25","current":43.395465,"twenty":15.741453,"median":31.201154,"eighty":79.929106,"marketCap":42824171488.68},{"date":"2024-10-31","current":45.076313,"twenty":15.741453,"median":31.201154,"eighty":79.086292,"marketCap":44338714216.59},{"date":"2024-11-08","current":23.061963,"twenty":15.732274,"median":30.643838,"eighty":78.376176,"marketCap":43661674072.7},{"date":"2024-11-15","current":23.302476,"twenty":15.732274,"median":30.454139,"eighty":52.554614,"marketCap":43374550679.55},{"date":"2024-11-22","current":22.482544,"twenty":15.732274,"median":30.401826,"eighty":52.071623,"marketCap":42186009596.39},{"date":"2024-11-29","current":22.318557,"twenty":15.732274,"median":30.334902,"eighty":51.88887,"marketCap":42718018145.77},{"date":"2024-12-06","current":22.537206,"twenty":15.732274,"median":30.202359,"eighty":51.680009,"marketCap":43528672494.7},{"date":"2024-12-13","current":22.602801,"twenty":15.732274,"median":30.13984,"eighty":51.23618,"marketCap":43060561658.31},{"date":"2024-12-20","current":22.438814,"twenty":15.732274,"median":30.092447,"eighty":51.014265,"marketCap":41267393050.42},{"date":"2024-12-27","current":22.89251,"twenty":15.732274,"median":30.057852,"eighty":50.68792,"marketCap":42014127583.17},{"date":"2025-01-03","current":22.854246,"twenty":15.732274,"median":30.013965,"eighty":50.217983,"marketCap":42075712866},{"date":"2025-01-10","current":22.526274,"twenty":15.7304,"median":29.981195,"eighty":49.163236,"marketCap":41357424220.33},{"date":"2025-01-17","current":22.072578,"twenty":15.7304,"median":29.8898,"eighty":48.45572,"marketCap":41218860202.53},{"date":"2025-01-24","current":22.056179,"twenty":15.7304,"median":29.842804,"eighty":47.722096,"marketCap":41006037214.49},{"date":"2025-01-31","current":32.066996,"twenty":15.7304,"median":29.792729,"eighty":47.270589,"marketCap":43228239899.45},{"date":"2025-02-07","current":31.518451,"twenty":15.7304,"median":29.792729,"eighty":46.516772,"marketCap":43185471262.61},{"date":"2025-02-14","current":31.625402,"twenty":15.7304,"median":29.792729,"eighty":46.191026,"marketCap":43025162552.6},{"date":"2025-02-21","current":32.135858,"twenty":15.7304,"median":29.792729,"eighty":46.13785,"marketCap":44672438730.76},{"date":"2025-02-28","current":33.019632,"twenty":15.7304,"median":29.792729,"eighty":45.930637,"marketCap":45808555597.44},{"date":"2025-03-07","current":33.965435,"twenty":15.728527,"median":29.788798,"eighty":45.798539,"marketCap":47684395829.03},{"date":"2025-03-14","current":33.616527,"twenty":15.728527,"median":29.788798,"eighty":45.697226,"marketCap":47372923461.69},{"date":"2025-03-21","current":33.462021,"twenty":15.728527,"median":29.788798,"eighty":45.536889,"marketCap":46793573769.54},{"date":"2025-03-28","current":32.837181,"twenty":15.728527,"median":29.788798,"eighty":45.417077,"marketCap":45256999058.78},{"date":"2025-04-04","current":32.910692,"twenty":15.728527,"median":29.788798,"eighty":45.358128,"marketCap":46930689894.65},{"date":"2025-04-11","current":28.911716,"twenty":15.7304,"median":29.784868,"eighty":45.194712,"marketCap":41677459532.98},{"date":"2025-04-17","current":30.639215,"twenty":15.7304,"median":29.784868,"eighty":45.124941,"marketCap":44845997107.55},{"date":"2025-04-25","current":31.299454,"twenty":15.728527,"median":29.784868,"eighty":45.06475,"marketCap":45645722852.58},{"date":"2025-05-02","current":32.102637,"twenty":15.728527,"median":29.784868,"eighty":45.020529,"marketCap":45944348076.13},{"date":"2025-05-09","current":61.722992,"twenty":15.728527,"median":29.784868,"eighty":44.978649,"marketCap":45906562811.51},{"date":"2025-05-12","current":58.311754,"twenty":15.728527,"median":29.784868,"eighty":44.978649,"marketCap":42498183485.5}],"updateTime":1747128618067}}}